| Literature DB >> 28970797 |
Chuandong Wang1, Weien Yuan2, Fei Xiao1, Yaokai Gan3, Xiaotian Zhao2, Zhanjing Zhai3, Xiaoying Zhao4, Chen Zhao5, Penglei Cui1, Tuo Jin2, Xiaodong Chen1, Xiaoling Zhang1,4.
Abstract
Small-interfering RNA (siRNA) provides a rapid solution for drug design and provides new methods to develop customizable medicines. <span class="Chemical">Polyethyleneimine 25 kDa (<span class="Chemical">PEI25kDa) is an effective transfection agent used in siRNA delivery. However, the lack of degradable linkage causes undesirable toxicity, hindering its clinical application. We designed a low-molecular-weight cross-linked polyethylenimine named PEI-Et (Mn:1220, Mw:2895) by using degradable ethylene biscarbamate linkage with lower cytotoxicity and higher knockdown efficiency than PEI25kDa in delivery Chordin siRNA to human bone mesenchymal stem cells (hBMSCs). Suppression of Chordin by using anti-Chordin siRNA delivered by PEI-Et improved bone regeneration in vitro and in vivo associated with the bone morphogenetic protein-2 (BMP-2) mediated smad1/5/8 signaling pathway. Results of this study suggest that Chordin siRNA can be potentially used to improve osteogenesis associated with the BMP-2-mediated Smad1/5/8 signaling pathway and biodegradable biscarbamate cross-linked low-molecular-weight polyethylenimine (PEI-Et) is a therapeutically feasible carrier material to deliver anti-Chordin siRNA to hBMSCs.Entities:
Keywords: Chordin; bone morphogenetic protein-2; human bone mesenchymal stem cells; low-molecular-weight polyethylenimine; osteogenesis
Year: 2017 PMID: 28970797 PMCID: PMC5609535 DOI: 10.3389/fphar.2017.00572
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810